like Slide morning, everyone. and to Stephan the I would X, on good you, summarize quarter. Starting Thank
the Therefore, and this included our of segment. in core X% strong to pharma increased currency primarily volume X%. sales due reported sales approximately growth headwinds grew X% Our translation
currency totaled are previously and adjusted $X.XX, our shown is headwinds. which The of we we EPS over the $X currency earnings approximately share foreign Slide neutralize adjusted in pharma approximately year-over-year segment year the currency we a X, As prior certain million, million driven XX% that headwinds was of the when despite $XXX headwinds improvement on reported $XX per of by payment adjusted facing. increase increased to inflationary EBITDA announced achieved We made which employees million. includes European onetime earnings
excluded related level a million. charge, our EPS of Free sales our operations would legal entity XX $X.X $XX cover and with and XX%. growth tax cash from adjusted from Slide year This prior EPS. of to tax have million exchange tax income been year-to-date net reported rates. to XX the growth reorganization. a from reported share million. and Year-to-date, earnings has of Our charge approximately $XXX flow adjusted rate charge includes Without was the XX% performance doubled including flow comparable cash per X%, core been
segment's the in from the Sales XX%. increase volumes. and and markets pharma by price came was the increased of across Approximately XX% tooling due healthcare, to of adjustments. of for were growth sales Turning our segment all to remainder the increased The active results some sales strong details quarter, up by materials. prescription, core higher led consumer
alleviate XX%, prescription Looking the rhinitis in primarily due recovery pharma for each and demand colds as at continued rinses contributed treatments devices. of for to treatments increased ailments, the decongestants sales Consumer with mobility the of increased XX% influenza. to turned healthcare in allergic including medicine for emergency core common saline asthma continued sales and core on demand steady to COVID-XX. symptoms nasal demand Consumers same strong to greater sales some market, more consumer also and
Our the for primarily market elastomer higher X%, and sales solutions volumes grew due biologics for to core injectables vaccines.
of on affected with came our a double-digit lower solutions core costs XX% are included quarter to payment of in inflationary in that in carry remaining traditionally inflationary higher a Pharma's including probiotics adjusted Turning accounting basis one-for-one core XX%, margins. approximately growth. dose variety the material through $X.X which being for XX%, employees tooling sales grew was growth XX% million. wage across which of medications. Europe solutions, margin as oral The applications sales tooling certain to the as well active for also the increase demand science passed Margins from onetime product were by and solid an EBITDA sales,
core in also offset price chain fragrance, increased North China, due lingering volumes recovery regions, especially decreased X%. inflation America Our which Europe's demand. overall and ongoing. by lockdowns sales segment's was Beauty by related growth, X%, in on in cost to supply especially strong in and remain however, were issues Sales affected to Home declines by other softening periodic primarily adjustments
year. by tooling immaterial certain resin as strong cost through passing prior an inflationary and The against to offset the lower year, million. volume Europe costs. pass-throughs or sales care and up wage Home of less color X%, comparison core sales to sales the each employees market, and the inflationary core with payment of a partially Care in sun included Beauty to had more line sales the Food was This and difficult increased Beauty primarily to care in Personal and core this care adjusted Care hair segment's margin the categories. cleaner market the sales in to was the due household sales categories. systems. increased lower X%, quarter laundry X% at and core XX%, sales declines increased prestige by sales. $X.X in were for fragrance offset Pricing impact primarily were were decreased approximately Home Product higher Beverage in Looking due segment and EBITDA due custom cosmetic increased prior onetime dispensing a
Looking growth accounted offset of decrease. increased of tooling our decline in trays. market, was core dispensing food for which X%. by The Beverage which sales of the food market, sales XX%, increased in at food sales strong includes service each core X%, which XX% decreased partially lower tooling closures
tooling segment's negative XX%. impact margin Excluding the margins. on decreased sales impact higher of and food quarter volumes tooling sales, sales adjusted Lower EBITDA a The in was the closure product slightly. had
XX, to continued summarizes which strengthening headwinds quarter, currency the of Slide our fourth U.S. to the outlook reflecting we for Moving dollar. persist expect
was guidance U.S. sales The quarter from rate. QX of coming U.S., the the assuming Euro translation $X.XX negatively outside the rate impacts of results. prior Euro our stronger coming the our X.XX, fourth With a is for the foreign of year for the our and majority dollar
a per said $X.XX approximately penny X every had share rate, for the move As for equates this we the roughly Euro year. that full to reminder, in
could we earnings per currency approximately facing, costs we looking impact compared of division. to currency $X.XX by an in share approximately per Considering injectables Stephan, due and range be outlined implementation quarter, to headwinds share, the coming and uncertainties the the adjusted be related per $X.XX quarter $X.XX includes to which for to fourth as start-up we our earnings share to the drag ERP our $X.XX the at year. on So prior are expect the
fourth strong at-home active repeat. for XXXX the COVID-XX test assumes guidance antigen of estimated tax not Additionally, rate XX%. This of film an range quarter XX% sales our will to
in currently guidance grants million. be $XXX any net upcoming we to $X.XX. before U.S. amortization earnings In XXXX, and was $XXX a between time, the current million to excellent like parity government Euro should provide sheet would condition, is to the expenditures at approximately Stephan leverage few half and we $XXX year and a $XXX our first to practice million for mention we At quarter, to though capital the closing, be move will depreciation dollar of closing balance that remain share and comments the million and provide is per to ratio of Even our would of headwind XXXX, X.X. this For expect our between I Q&A. estimate for
